Banner for leaf pages 2

Topiramate (Topamax)

Also known as Topamax


Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. It was most recently approved for weight loss by the FDA in combination with phentermine. It has been used off-label for this purpose before FDA approval was obtained. It was originally produced by Ortho-McNeil Neurologics and Noramco, Inc., both divisions of the Johnson & Johnson Corporation. It was also recently approved in a combination medication used for weight loss in late 2012. This medication was discovered in 1979 by Bruce E. Maryanoff and Joseph F. Gardocki during their research work at McNeil Pharmaceutical. Topiramate was first approved by the US FDA in 1996. Generic versions are available in Canada and these were approved by the Food and Drug Administration (FDA) in September 2006. Mylan Pharmaceuticals was recently granted final approval for generic topiramate 25, 100, and 200 mg tablets and sprinkle capsules by the FDA for sale in the United States. 50 mg tablets were granted tentative approval. The last patent for topiramate in the U.S. was for pediatric use; this patent expired on February 28, 2009.

Source: Wikipedia

DEA Class 4 meaning a low potential for abuse and low risk of dependence.

Estimated Total Cost: $67.2 for an average of 28 days supply

What is it prescribed for?

Patients are most commonly prescribed topiramate to treat migraine, epilepsy, seizures, and cerebral palsy.

What drug interactions are known?

Do not take topiramate if you are taking any of the following:

Critical Interactions

Significant Interactions

Ajax-loader Loading...